Ann: Paradigm to Present at Evercore ISI HealthCONx Conference, page-149

Agreed, don't take your eye off the prize.

Of course don't be silly about it, you must employ corect money management,......but our data hasn't changed, the AE's tab on the MOZZ Negatives spreadsheet hasn't gone up (from ZERO)....yes a few POTENTIAL months MIGHT been added, but the 15 B Plus prize is still there, and you know what, this isn't necessarily random like tattslotto can be....there is a real chance of this working out....re-read the data that has been published...enjoy reading the MOA again as reminder of what we own...here are a couple of links for the new guys that have no idea what I'm on about and for the older of us that might have forgotten...


LINK 1:

https://asx.api.markitdigital.com/asx-research/1.0/file/2924-02152739-3A525143?access_token=83ff96335c2d45a094df02a206a39ff4

Point: We have an effective agent symptomatically AND we have a drug that APPEARS to address cartliage degeneration

A snipet:








LINK 2 :
https://paradigmbiopharma.com/investors/asx-announcements/?sl-year=2019

Point: COMP, a biomarker, a sure way of detecting OA goes DOWN as a result of iPPS's action while Placebo went UP
ADAMTS-5 also was reduced while Placebo went up!

A snipet:










Remind yourself before you sell your holdings that this is what you owned and what it is capable of, it has never be shown before by ANY drug, ever in terms of OA and NGF pain.


My views , DYOR etc